22 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
28 May 21
Current report (foreign)
6:03am
, Business Continuity Plans have been developed for key risks concerning, for example, manufacturing sites and IT cybersecurity. For crisis … the following actions for cybersecurity: The Information Security & Governance Board continued to meet monthly and on an ad hoc basis. This body consists
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
12:00am
been developed for key risks concerning, for example, manufacturing sites and IT cybersecurity. For crisis management, the Company has developed … checks at global level in relation to key privacy risks. ▪ The Company conducted the following actions for cybersecurity: – The Information Security
6-K
TAK
Takeda Pharmaceutical Co
27 May 20
Current report (foreign)
6:05am
training modules were developed and deployed to the global workforce to strengthen cybersecurity awareness in the context of emerging threats … to counter evolving cyber threats. Insurance coverage was obtained to reimburse certain costs related to significant cybersecurity events that Takeda
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
23 Jun 23
Current report (foreign)
6:13am
assurance activities at global level in relation to key privacy risks. The Company conducted the following actions for cybersecurity: Since … the Company recognized the critical role that cybersecurity plays in ensuring trusted digital interactions with the Company’s stakeholders, the Company
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 May 23
Current report (foreign)
6:11am
various assurance activities at global level in relation to key privacy risks. The Company conducted the following actions for cybersecurity: Since … the Company recognized the critical role that cybersecurity plays in ensuring trusted digital interactions with the Company’s stakeholders, the Company
6-K
znhinfc njmp
19 Jul 21
Current report (foreign)
6:02am
6-K
ws7zx7s6oa0emr0
11 Jul 22
Current report (foreign)
6:05am
6-K
3j78k
1 Nov 21
Current report (foreign)
6:04am
6-K
EX-99.1
3pjmuq hhkn
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
cij2y8 h8
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
mtt44eoln1wz
30 May 19
Current report (foreign)
10:26am
424B3
zt2blps8
14 Nov 19
Prospectus supplement
6:10am
20-F
hqwrxkp3jp2nn7lkqpg
27 Jun 19
Annual report (foreign)
6:41am
F-4
rx99yzavx0w1bu
9 Aug 19
Registration of securities (foreign)
6:27am
20FR12B/A
q6tn1wm
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
DRS/A
ctlqo 9xur6cw
16 Nov 18
Draft registration statement (amended)
12:00am
F-4/A
y2hy8 115ckx55
12 Nov 19
Registration of securities (foreign) (amended)
9:50am